Possible scenarios of the development of antibiotic resistance in patients with urinary tract infection after the COVID-19 pandemic era
Abstract
An outbreak of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the causative pathogen for COVID-19 was reported at the end of December 2019 in Wuhan, Hubei province, China, and by March 2020, it was declared a pandemic COVID-19. In hospital and critical care department settings, the majority of patients with COVID-19 receive broad-spectrum antibiotics for treatment of secondary infection complications. In patients affected by COVID-19, who had a suspected secondary bacterial superinfection, antibiotics including teicoplanin, clarithromycin, doxycycline, azithromycin, tetracyclines, levofloxacin, moxifloxacin, ciprofloxacin, and cephalosporins 3d generation were proposed as an effective treatment. In this editorial, we will consider possible scenarios of the development of antibiotic resistance after the pandemic COVID-19 in patients with urinary tract infection (UTI).
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.